QuantumPharm Inc. (HKG: 2228), operating as XtalPi Inc., reported 2025 financial results, achieving first annual profitability with net profit of RMB 135 million (USD 19.6 million). The company became the first profitable Hong Kong-listed company in the AI for Science (AI4S) sector, with global sales skyrocketing 201.2% YoY to RMB 803 million (USD 116 million). The drug discovery solutions business drove exceptional growth, surging 418.9% to RMB 538 million fueled by antibody business expansion and milestone achievements across partner pipelines.
Profitability supports premium valuation vs. pre-revenue AI biotech peers; potential index inclusion (Hang Seng Tech)
2026 Catalysts: Additional profitability quarters; major pharma partnership announcements; AI model regulatory validation (FDA/EMA engagement on AI-generated INDs)
Competitive Landscape: Positions against Schrödinger (SDGR), Recursion (RXRX), Insilico Medicine; XtalPi’s first profitability + China market depth provides differentiation
Forward‑Looking Statements This brief contains forward‑looking statements regarding sustained profitability, partner pipeline progression, and AI model regulatory acceptance. Actual results may differ due to partner milestone timing, competitive AI platform development, and macroeconomic factors affecting biotech R&D spending.-Fineline Info & Tech
Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.
